

# Table S1

Table S1. Generation of 100 T isolates from plasma and peripheral blood mononuclear cells of 10 prospectively sampled individuals

		Number of TP strains <sup>2</sup>	Date <sup>3</sup>	PCRs <sup>4</sup>	Viral load (copies/mL)	CD4 count (cells/μL)	Number of B2M-derived viral sequences (plasma) <sup>5</sup>	Number of B2M-derived viral sequences (PBMC) <sup>6</sup>	Number of testing elution isolates (plasma) <sup>7</sup>	Number of bulk isolates (plasma) <sup>8</sup>	Number of outgrowth viruses (PBMC) <sup>9</sup>		
WM14	2		21-Jun-01	11	6,233,800								
			12-Jul-01	20	1,889,800	420							
			20-Jul-01	40	27,611,800	430	8			3 (2)			
	11		2-Aug-01	35	873,400	830							
			8-Aug-01	80	269,000	880							
			26-Oct-01	130	15,800	430	8				1		
			6-Dec-01	170	27,200	380							
			1-Mar-02	210	82,700	380	3				1		
			11-Nov-02	310	60,300	380	15				2		
			9-Jan-03	120	16,000	420							
			2-Jun-03	120	66,800	250	8				2 (0)		
			8-Oct-03	308	30,100	230							
			20-Jun-04	1,658		3	3				2 (0)		
			6-Oct-04	1,212	6,100	320							
			26-Jan-06	1,326	12,800	210	8				1		
			2-Aug-06	1,266	16,700	340	4				1		
			1-Aug-06	1,813	82,800	210							
			16-Sep-06	1,862		200							
			18-Jun-08	1,680	18,000	280							
			13-Feb-08	1,708	180	368							
			27-Mar-08	1,750	80	380							
			26-Jun-08	1,832	80	270							
			27-Nov-08	1,888	200	440							
			16-Feb-09	2,080	80	830							
		18-Jun-07	2,188	30	820								
		28-Nov-07	2,383	30	880								
	30-Sep-08	2,668	30	610									
	6-Mar-08	2,828	30	820									
	16-Mar-08	2,987	30	880									
	6-Nov-08	3,076	30	710									
	8-May-10	3,193	30	830						1			
	13-Mar-12	3,830	30	780									
	23-Oct-12	4,817	280	840									
WM18	1		6-Sep-01	8	39,000								
			21-Sep-01	20	10,800	1,890							
			28-Sep-01	27	13,300	1,200	16			3 (0)			
	11		8-Oct-01	37	28,800	1,330	17			4 (0)			
			16-Oct-01	44	28,800	870							
			20-Oct-01	58	127,000	880							
			19-Nov-01	78	88,800	1,480	11			1 (0)			
			17-Dec-01	120	387,300	820	15			1 (0)			
			11-Mar-02	191	43,200	880	8			1 (0)			
			10-Jun-02	282	110,100	820							
			9-Dec-02	373	49,200	420	7			1 (0)			
			9-Dec-02	484	88,800	370							
			3-Mar-03	568	40,700	260	6			1 (0)			
			17-Apr-03	583	16,400	280							
			10-Apr-03	608	38,700								
			9-Jun-03	698	23,800	240							
			22-Aug-03	728	37,800	360	8			1			
			19-Oct-03	798	70,000	730							
			10-Dec-03	820	70	680							
			9-Jan-04	880	30	880							
			23-Mar-06	1,038	30	430							
			18-Dec-04	1,200	30	880							
			11-May-05	1,348	30	980							
			8-Jul-06	1,803	30	700					1		
			6-Jun-06	1,887	30	880							
			23-Aug-06	1,916	30	820							
			16-Jun-07	1,963	200	970							
			9-Dec-07	2,198	30	840							
			23-Jan-08	2,338	30	700							
			12-Jun-08	2,476	30	780							
			9-Jan-09	2,687	30	800							
			28-Apr-09	2,787	280	880							
			03-May-10	2,813	30								
			1-Feb-10	2,878	30	1,000							
			1-Sep-11	2,882	80	830							
		WM21	1		9-Mar-02	8	11,100,300	330	41		12		
					11-Mar-02	15	6,817,700	210					
	16-Mar-02			22	6,182,100	210							
10			2-Apr-02	37		800							
			28-Apr-02	66	300,800	880	8			8			
			17-Jun-02	110	147,700	810							
			16-Sep-02	204	117,400	330	43			8			
			6-Jan-03	276	100,100	300			15				
			3-Jul-03	486	76,300	410							
			20-Sep-03	583	115,000	220							
			17-Nov-03	624	71,200	380							
			16-Feb-04	724	33,400	100	9						
			19-Mar-04	874	41,600	230							
			9-Jul-04	881		320							
			30-Nov-04	1,019	167,800	230							
			26-Jan-06	1,088	46,700	240			6				
			1-Aug-06	1,254	108,800	230							
			8-May-06	1,338	168,000	180			8				
			26-Jun-06	1,586									
			17-Jul-08	1,808	200	280							
			2-Oct-08	1,888	380	880	8						
			26-Feb-09	1,828	30	230							
			8-Jul-09	1,887	30	280							
			17-Dec-07	2,132	30	280							
			16-Apr-08	2,342	30	280							
			1-Sep-08	2,380	30	280							
			4-Dec-08	2,476	30	310							
			10-Mar-09	2,580	30	400							
			23-Aug-09	2,738	30	380	31				2		
			23-Feb-10	2,828	30	380							
			17-Mar-11	3,168	30	380							
			19-Jan-12	3,482	30	720							
			7-Oct-12	3,787	30	710							
	12-Jan-15	3,888	30	1,130									
WM22	2		21-Jul-03	17	28,800	870	40		16				
			26-Jul-03	25	16,800	780							
			9-Aug-03	32	21,400	880							
	16		14-Aug-03	47	18,400	830							
			18-Aug-03	48	6,800	730							
			16-Sep-03	76	2,800	820	10			1			
			16-Oct-03	100	9,800	670							
			12-Jan-04	182	9,800	830	40			3			
			20-Jun-04	282	9,800	880	18						
			20-Sep-04	484	8,200	800							
			9-Nov-04	600	9,800	810							
			2-Aug-05	800	11,400	800			8				
			8-Feb-07	1,212	60,700	430	12			7			
			3-May-07	1,388	18,000	480			2				
			2-Aug-05	160	9,800	870	15						
			16-Feb-06	180	16,000	820			8				
			17-Aug-06	2,000	18,000	240			16				
			16-Oct-06	2,288		280							
			18-Oct-06	2,320	80	480							
			23-Feb-10	2,436	30	830							
			26-Oct-10	2,878	30	830							
			10-Jan-11	2,937	30	820							
			23-Jun-11	2,911	30	820							
			3-Mar-11	3,048	30	880							
			1-Jun-12	3,240	30	780					1		
			21-Feb-12	3,820	30	730					2		
		WM23	1		21-Apr-04	3	2,203,800						
					23-Apr-04	8	388,800	810					
					26-Apr-04	8		800					
			10		26-Apr-04	15	1,808,000	880	30 <sup>a</sup>		10 <sup>a</sup>		
					11-May-04	23	9,700	820					
					26-May-04	37	7,400	820	21 <sup>a</sup>				
					22-Jun-04	48	800	830					
					16-Jul-04	82	3,800	810	12 <sup>a</sup>				
					2-Sep-05	137	8,400	880			8 <sup>a</sup>		
					16-Oct-05	176	7,800	870	12 <sup>a</sup>				
					12-Jun-06	278	18,400	830	18 <sup>a</sup>				
					7-Apr-06	384	89,000	810			10 <sup>a</sup>		1
	21-Jul-06			438	35,800	810							
	13-Oct-06			583	16,000	880	21 <sup>a</sup>						
	17-Jan-08			838	16,800	480	19 <sup>a</sup>		8 <sup>a</sup>		1		
	16-Jul-06			921	16,400	880	19 <sup>a</sup>		9 <sup>a</sup>				
	21-Oct-06			926	28,700	480							
	23-Jan-07			1,010	40,200	480							
	7-Aug-07			1,206	280,000	190	10 <sup>a</sup>		13 <sup>a</sup>		3&gt		



# Table S3

Table S3. Number of viral isolates from ART suppressed individuals with and without treatment interruption

Virus	Subjects <sup>1</sup>	Gender <sup>2</sup>	Years on ART before ATI <sup>3</sup>	Sample time point	Viral load (copies/μl)	CD4 count (cells/μl)	Sample <sup>4</sup>	Number of Limiting dilution virus Isolates <sup>5</sup>	Study Number	References
VOA	B199	M	4	second leukapheresis	<20	200	QVOA Supernatant	1	MNU-0628	Lorenzi et al., 2016
VOA	B106	M	7	first and second leukapheresis	<20	390	QVOA Supernatant	2		
VOA	9242	M	2	during ATI (12 weeks) before rebound	<20	967	QVOA Supernatant	2	NCT02825797	Mendoza et al., 2018
VOA	9243	M	5	during ATI (12 weeks) before rebound	<20	545	QVOA Supernatant	1		
VOA	9244	M	5	2 weeks pre ATI	<20	796	QVOA Supernatant	4		
VOA	9244	M	5	during ATI (12 weeks) before rebound	<20	796	QVOA Supernatant	2		
VOA	9241	M	5	during ATI (12 weeks) before rebound	<20	709	QVOA Supernatant	1		
VOA	9241	M	5	2 weeks pre ATI	<20		QVOA Supernatant	4		
Rebound	9242	M	2	16 weeks post ATI	65,520	450	Plasma	5		
Rebound	9243	M	5	21 weeks post ATI	10,110	350	Plasma	1		
Rebound	9244	M	5	22 weeks post ATI	120,330	730	Plasma	5		
Rebound	9241	M	5	22 weeks post ATI	13,250	500	Plasma	1		
VOA	A06	M	>3.6	2.5 weeks pre ATI	<50	>470	QVOA Supernatant and cryopreserved PBMC	6	NCT02463227	Bar et al., 2016; Salantes et al., 2018
VOA	A06	M	>3.6	10.5 months post ATI	<50		QVOA Supernatant	3		
VOA	A08	M	>3.6	4 weeks pre ATI	<50	>470	QVOA Supernatant	4		
VOA	A08	M	>3.6	11 months post ATI	<50		QVOA Supernatant and cryopreserved PBMC	16		
VOA	A09	M	>3.6	1 week pre ATI	<50	>470	QVOA Supernatant	4		
VOA	A09	M	>3.6	12 months post ATI	<50		QVOA Supernatant	2		
Rebound	A09	M	>3.6	3 weeks post ATI	2,330	>350	Plasma	8		
Rebound	A08	M	>3.6	5 weeks post ATI	20,000	>350	Plasma	17		
Rebound	S22	M	8	during 2nd ATI	750,000	449	Plasma	5	NCT00051818	Papasavvas et al., 2004
Rebound	S23	M	5	during 2nd ATI	556,372	351	Plasma	2		
Rebound	S30	M	5	during 3rd ATI	517,473	467	Plasma	4		
Rebound	004	M	>1	4 weeks post ATI (week 12 of study)	33,812	794	Plasma	4	NCT02227277	Azzoni et al, 2020
Rebound	030	M	>1	4 weeks post ATI (week 12 of study)	18,056	377	Plasma	4		
Rebound	044	F	>1	4 weeks post ATI (week 12 of study)	20,171	496	Plasma	4		
Rebound	601	M	20	5 weeks post ATI (week 29 of study)	112,160	707	Plasma	6	NCT02588586	Cohen et al., 2018

<sup>1</sup>All subjects were recruited in the US and had subtype B infections, except for subject A09 who also had a subtype A strain (only subtype B viruses were isolated)

<sup>2</sup>M, male; F, female.

<sup>3</sup>ATI, analytical treatment interruption

<sup>4</sup>QVOA, quantitative viral outgrowth assay

<sup>5</sup>Viral isolates were confirmed by sequence analysis to be single virion-derived (Genbank accession number are shown in Table S X)

# Table S4

Table S4. Biological characterization of viral outgrowth and rebound isolates

Type <sup>1</sup>	Isolate ID <sup>2</sup>	Study number	Replicative capacity (ng p24/ml) <sup>3</sup>	Isolate tropism <sup>4</sup>	IFN $\alpha$ 2 IC <sub>50</sub> (pg/ml) <sup>5</sup>	IFN $\beta$ IC <sub>50</sub> (pg/ml) <sup>7</sup>	sCD4 IC50 (ug/ml) <sup>7</sup>	CD4-Ig IC50 (ug/ml) <sup>7</sup>	Infectivity (IU/pg RT)	p24 Particle release (%) <sup>9</sup>
VOA	B199.2.C.BF.1	MNU-0628	80		0.04	0.12				
VOA	B106.1.C.3.8 <sup>11</sup>		100		0.18	3.12				
VOA	B106.2.C.D6.S8 <sup>11</sup>		195		0.16	1.96				
VOA - week 12 <sup>10</sup>	9242.VOA.12F23	NCT02825797	386	R5	0.02	0.04	>20	>20	39.33	
VOA - week 12 <sup>10</sup>	9242.VOA.12M6		641	R5	0.01	0.01	>20	17.43	79.48	
VOA - week 12 <sup>10</sup>	9243.VOA.12Y10		679	R5	0.02	0.04	>20	17.03	76.88	
VOA - week 12 <sup>10</sup>	9244.VOA.12I10		492	R5	0.02	0.04	>20	1.73	14.14	
VOA - week 12 <sup>10</sup>	9244.VOA.12I17		483	Dual	0.02	0.09	>20	>20	30.82	
VOA - week -2 <sup>10</sup>	9244.VOA.G12		694	R5	0.01	0.10	>20	>20	17.29	
VOA - week -2 <sup>10</sup>	9244.VOA.H1		496	R5	0.02	0.06			45.21	
VOA - week -2 <sup>10</sup>	9244.VOA.K2		404	Dual	0.02	0.15	>20	>20	46.79	48%
VOA - week -2 <sup>10</sup>	9244.VOA.P11		423	R5	0.02	0.11	>20	10.97	139.08	
VOA - week 12 <sup>10</sup>	9241.VOA.12AU7		360	Dual	0.03	0.25			174.31	56%
VOA - week -2 <sup>10</sup>	9241.VOA.D2		445	R5	0.02	0.09			2.54	42%
VOA - week -2 <sup>10</sup>	9241.VOA.A10		315		0.04	0.13				
VOA - week -2 <sup>10</sup>	9241.VOA.C19		282		0.04	0.09				
VOA - week -2 <sup>10</sup>	9241.VOA.C8		278		0.04	0.10				
Rebound	9242.REB.6B8		299	R5	1.13	45.04			4.59	
Rebound	9242.REB.6A7 <sup>12</sup>		309	R5	1.05	21.99			5.63	53%
Rebound	9242.REB.6B2 <sup>12</sup>		286	R5	1.93	30.49			15.69	
Rebound	9242.REB.13B1 <sup>12</sup>		547	R5	1.26	61.88			9.93	
Rebound	9242.REB.13B6 <sup>12</sup>		418	R5	1.70	58.24			9.68	
IMC	9242.REB.r1 <sup>12</sup>		108	R5	2.08	46.67			3.54	
Rebound	9243.REB.13F7		554	R5	1.56	49.26			10.58	
Rebound	9244.REB.7A8		499	R5	1.53	54.25			6.41	81%
Rebound	9244.REB.7A1		459	R5	1.59	31.67			6.05	
Rebound	9244.REB.7C1		567	R5	1.72	34.43			4.14	
Rebound	9244.REB.9D3		578	R5	1.35	48.06	>20	10.21	27.08	61%
Rebound	9244.REB.9E6		535	R5	1.70	77.03	>20	>20	136.72	81%
Rebound	9241.REB.7D4		626	R5	1.62	82.64	>20	>20	4.82	91%
VOA - Pre ATI	A08.VOA.M5	NCT02463227	139	R5	0.15	1.70	>20	>20	71.20	52%
VOA - Pre ATI	A08.VOA.M10		144	R5	0.11	1.57	>20	>20	42.78	22%
VOA - Pre ATI	A06.VOA.M30		158	R5	0.09	1.81	>20	>20	62.60	28%
VOA - Pre ATI	A06.VOA.M28		97	R5	0.09	1.17			83.36	
VOA - Pre ATI	A06.VOA.M19		150	R5	0.08	1.40			54.54	38%
VOA - Pre ATI	A06.VOA.M29		124	R5	0.07	2.99			128.33	
VOA - Post ATI	A06.VOA.2B		143	R5	0.07	0.85			128.52	51%
VOA - Post ATI	A06.VOA.M20		126	R5	0.09	1.67			121.20	48%
VOA - Post ATI	A06.VOA.M3		117		0.09	1.10				
VOA - Pre ATI	A08.VOA.1E2		99	X4	0.04	0.32			75.20	
VOA - Pre ATI	A08.VOA.M1		1548	Dual	0.02	0.01	>20	>20	14.96	
VOA - Pre ATI	A08.VOA.M4		965	X4	0.01	0.04			43.40	49%
VOA - Pre ATI	A08.VOA.M5		665	X4	0.01	0.10			16.78	24%
VOA - Post ATI	A08.VOA.M17		977	Dual	0.01	0.60			20.23	
VOA - Post ATI	A08.VOA.M20		620	X4	0.01	0.08			8.64	31%
VOA - Post ATI	A08.VOA.1B5		122	X4	0.03	0.90	>20	>20	8.29	
VOA - Post ATI	A08.VOA.1C8		152	X4	0.03	0.08			4.35	
VOA - Post ATI	A08.VOA.1F8		163	Dual	0.03	0.07			4.44	
VOA - Post ATI	A08.VOA.3D8		65	R5	1.47	5.17			6.04	
VOA - Post ATI	A08.VOA.4A1		103	X4	0.02	0.15	>20	>20	13.91	
VOA - Post ATI	A08.VOA.4E4		120	X4	0.02	0.09	>20	>20	15.37	
VOA - Post ATI	A08.VOA.5C3		83	X4	0.03	0.39			2.93	
VOA - Post ATI	A08.VOA.5E2		142	X4	0.02	0.03	>20	>20	13.11	
VOA - Post ATI	A08.VOA.5E4		119	Dual	0.04	0.49			1.83	
VOA - Post ATI	A08.VOA.6D3		120	X4	0.03	0.04			11.00	
VOA - Post ATI	A08.VOA.6E2		86	X4	0.02	0.08			3.13	
VOA - Post ATI	A08.VOA.6F6		66	R5	1.23	8.24			8.84	
VOA - Post ATI	A08.VOA.7F8		150	Dual	0.04	0.14			3.36	
VOA - Post ATI	A08.VOA.8E8		50	Dual	0.03	0.03			2.65	
Rebound	A08.REB.1A3		451	Dual	1.06	83.13			2.50	94%
Rebound	A08.REB.1D1		496	Dual	1.45	51.37			5.98	87%
Rebound	A08.REB.5D2		125	R5	1.22	80.62			47.47	
Rebound	A08.REB.5D2		250	X4	1.44	45.34			29.40	
Rebound	A08.REB.6B3		125	R5	0.85	55.84			59.56	
Rebound	A08.REB.6D6		728	X4	1.22	46.83	>20	>20	40.83	
Rebound	A08.REB.7A3		504	X4	1.51	75.85			24.00	
Rebound	A08.REB.7C1		707	X4	1.43	68.06			24.61	
Rebound	A08.REB.7C2		176	R5	2.07	44.85			24.26	
Rebound	A08.REB.7D3		309	X4	1.65	38.78	>20	>20	25.16	
Rebound	A08.REB.8A5		768	X4	1.59	41.98	>20	>20	39.00	
Rebound	A08.REB.8B3		763	X4	1.61	41.17			46.30	
Rebound	A08.REB.8D1		425	X4	1.33	31.24	>20	>20	29.05	
Rebound	A08.REB.6B5		510	X4	2.28	64.49			142.66	
Rebound	A08.REB.8B5		510	X4	1.94	69.78			224.92	
Rebound	A08.REB.2F4		420		3.01	92.25				77%
IMC	A08.REB.2F4		66	R5	2.01	117.61			3.82	
Rebound	A08.REB.1A5		506	X4	1.69	42.34			1.31	84%
IMC	A08.REB.1A5		106	X4	2.70	49.23				
VOA - Pre ATI	A09.VOA.M25		194	R5	0.26	1.29			82.33	
VOA - Pre ATI	A09.VOA.M22		206	R5	0.05	0.19			115.31	
VOA - Pre ATI	A09.VOA.M2		254	R5	0.05	0.46			82.42	23%
VOA - Pre ATI	A09.VOA.M6		171	R5	0.06	0.70			110.34	49%
VOA - Post ATI	A09.VOA.M9		171	R5	0.21	0.06			45.72	
VOA - Post ATI	A09.VOA.M16		285	R5	0.05	0.69			74.11	
Rebound	A09.REB.1B5		275		3.16	58.67				
Rebound	A09.REB.1D5		101		2.19	51.20				
Rebound	A09.REB.2B2		171	R5	2.79	26.36			1.05	
Rebound	A09.REB.1A1		376	R5	2.40	46.03			7.73	73%
Rebound	A09.REB.1A3		227	R5	1.78	58.57			3.04	79%
Rebound	A09.REB.1A4		239	R5	2.48	70.36			3.01	
Rebound	A09.REB.1A5		249	R5	2.55	61.27	>20	>20	11.68	
Rebound	A09.REB.1A2		221	R5	2.54	83.45			5.30	74%
IMC	A09.REB.1A2		104	R5	1.63	142.15				
Rebound	S22.REB.24C4	NCT00051818	399	R5	1.64	90.59			5.50	74%
Rebound	S22.REB.1E2		389	R5	1.03	61.14			8.59	
Rebound	S22.REB.1F5		374	R5	1.62	93.32	>20	>20	12.95	
Rebound	S22.REB.3A6		487	R5	1.45	97.27	>20	9.977	21.40	74%
Rebound	S22.REB.3B6		378	R5	1.00	75.65	>20	>20	13.32	65%
Rebound	S23.REB.3D1		358	R5	1.70	66.56	>20	11.63	21.68	
Rebound	S23.REB.24A5		475	R5	1.25	76.30			29.05	
Rebound	S30.REB.8D1		407		1.21	84.20				
Rebound	S30.REB.2D1		303		2.14	87.20				
Rebound	S30.REB.2D2		350	R5	1.54	70.82			18.95	71%
Rebound	S30.REB.7D1		336	R5	1.72	72.69			3.42	85%
Rebound	004.REB.4D4	NCT02227277	413	R5	2.58	93.58	>20	>20	18.74	85%
Rebound	004.REB.4E6		263	R5	2.54	63.21	>20	>20	15.19	88%
Rebound	004.REB.4D1		259	R5	2.65	97.87	>20	>20	32.26	80%
Rebound	004.REB.4E3		252	R5	5.55	111.80	>20	>20	8.66	
Rebound	030.REB.3E1		371	R5	2.99	56.49			24.35	68%
Rebound	030.REB.2E1		396	R5	2.84	47.24			30.22	93%
Rebound	030.REB.4E1		427	R5	3.48	70.43			30.93	74%
Rebound	030.REB.8E1		308	R5	2.84	69.21			32.36	87%
Rebound	044.REB.6F1		283	R5	3.42	79.99			39.42	74%
Rebound	044.REB.5F1		348	R5	2.75	69.41			30.89	86%
Rebound	044.REB.7F1		329	R5	2.80	72.71			16.85	81%
Rebound	044.REB.8F1		355	R5	2.48	91.45			37.08	92%
Rebound	601.REB.4B7	NCT02588586	497	R5	2.15	64.85			28.56	
Rebound	601.REB.4C3		483	R5	2.03	33.29	>20	>20	30.56	73%
Rebound	601.REB.4B4 <sup>12</sup>		468	R5	2.17	65.81			13.49	74%
Rebound	601.REB.4A8 <sup>12</sup>		546	R5	1.81	42.24			11.98	71%
Rebound	601.REB.4A7 <sup>12</sup>		562	R5	2.25	60.84			12.89	64%
Rebound	601.REB.4C1 <sup>12</sup>		536	R5	2.02	54.66	>20	>20	20.30	72%
IMC	601.REB.r1 <sup>12</sup>		96	R5	1.68	91.79			3.58	

<sup>1</sup>Isolates were obtained by expanding viral outgrowth assay (VOA) supernatants as previously reported (Lorenzi et al., 2016; Bar et al., 2016; Salantes et al., 2018; and Mendoza et al., 2018) or generated de novo from cryopreserved PBMCs or plasma samples.

<sup>2</sup>Viral sequence identifier as submitted to GenBank (for accession numbers see Table S5).

<sup>3</sup>Concentration of p24 antigen in CD4<sup>+</sup> T-cell culture at day 7 postinfection in the absence of IFN treatment.

<sup>4</sup>Viral tropism as determined in TZMbl cells; cells were pretreated with AMD and Maraviroc prior to virus infection to inhibit interaction with CXCR4 and CCR5 cellular receptors, respectively.

<sup>5</sup>Dose of IFN that reduced viral replication in CD4<sup>+</sup> T cells by 50%.

<sup>6</sup>Concentration of soluble CD4 (sCD4) that reduced infectivity by 50% in a TZMbl neutralization assay.

<sup>7</sup>Concentration of CD4-Ig that reduced infectivity by 50% in a TZMbl neutralization assay.

<sup>8</sup>Infectious units per particle (picogram of RT) measured in TZM-bl cells.

# Table S5

Table S5. Virus replication in macrophages from different donors.

ID	Type	Virus	Source	Virus Tropism	sCD4 IC50 (ug/ml)	CD4-Ig IC50 (ug/ml)	Donors							
							ZB620	ZB624	ZB710	ZB28	ZB31	ZB722	ZB725	ZB668
MCST	Chronic	IMC	Parrish et al., PNAS 2013	R5			no	yes	yes	yes	no			
STC0r1	Chronic	IMC	Parrish et al., PNAS 2013	Dual			no	yes	no	no	yes			
THRO	Transmitted founder	IMC	Salazar-Gonzalez et al., J Virol 2009	R5			no	yes	yes	yes	yes			
TYBE***	Chronic***	IMC	Yi et al., J Virol 1999	X4						yes	yes			
UG021***	Chronic***	IMC	Gao et al., J Virol 1996	X4						yes	yes			
WITO	Transmitted founder	IMC	Salazar-Gonzalez et al., J Virol 2009	R5			no	yes	yes	yes	yes			
YU2***	Chronic***	IMC	Li et al., J Virol 1991	R5	0.9224	0.08674	no	yes	yes	yes	yes			
REJO	Transmitted founder	IMC	Salazar-Gonzalez et al., J Virol 2009	R5			no	yes	yes	yes	yes			
RHGA	Chronic	IMC	Parrish et al., PNAS 2013	R5			no	yes	yes	no	no			
RHPA	Transmitted founder	IMC	Salazar-Gonzalez et al., J Virol 2009	R5			no	yes	yes	yes	yes			
CH058	Transmitted founder	IMC	Salazar-Gonzalez et al., J Virol 2009	R5			no	yes	yes	yes	yes	yes	no	yes
CH077	Transmitted founder	IMC	Salazar-Gonzalez et al., J Virol 2009	Dual			no	yes	yes	yes	yes			
CH141	Chronic	IMC	Parrish et al., PNAS 2013	R5			no	yes	yes	yes	yes			
CH167	Chronic	IMC	Parrish et al., PNAS 2013	R5			no	yes	yes	yes	yes			
CH042	Transmitted founder	IMC	Parrish et al., PNAS 2013	R5			no	yes	yes	yes	yes			
CH470	Transmitted founder	IMC	Parrish et al., PNAS 2013	R5						yes	yes	yes	yes	yes
CH492	Chronic	IMC	Iyer et al., PNAS 2017	R5						no	no	no	no	no
MM33.TF	Transmitted founder	IMC	This study	R5						no	no			
MM33_13	Chronic	IMC	This study	R5						yes	yes			
MM33_17	Chronic	IMC	This study	R5						no	no			
9244.VOA.G12	VOA (week -2)	Isolate	Mendoza et al., 2018	R5	>20	>20	no	yes		yes	yes			
9244.VOA.K2	VOA (week -2)	Isolate	Mendoza et al., 2018	Dual	>20	>20	no	yes		yes	yes			
9244.VOA.P11	VOA (week -2)	Isolate	Mendoza et al., 2018	R5	>20	10.97	no	yes		yes	yes			
9244.VOA.12J17	VOA (week 12)	Isolate	Mendoza et al., 2018	Dual			no	yes		yes	yes			
9244.REB.9D3	Rebound	Isolate	This study	R5	>20	>20	yes	yes		yes	yes			
9244.REB.9E6	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
9241.REB.7D4	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
9242.REB.r1	Rebound	IMC	This study	R5			no	yes	yes	yes	yes	yes	yes	yes
A08.VOA.1B5	VOA (Post ATI)	Isolate	This study	X4	>20	>20				no	no	no	no	no
A08.VOA.1C8	VOA (Post ATI)	Isolate	This study	X4								no	no	
A08.VOA.1F8	VOA (Post ATI)	Isolate	This study	Dual								no	no	
A08.VOA.3D8	VOA (Post ATI)	Isolate	This study	R5								no	no	no
A08.VOA.4E4	VOA (Post ATI)	Isolate	This study	X4	>20	>20				no	no	no	no	no
A08.VOA.5E4	VOA (Post ATI)	Isolate	This study	Dual								no	no	no
A08.VOA.6D3	VOA (Post ATI)	Isolate	This study	X4								no	no	no
A08.VOA.6F6	VOA (Post ATI)	Isolate	This study	R5								no	no	no
A08.VOA.5E2	VOA (Post ATI)	Isolate	This study	X4	>20	>20						no	no	no
A08.VOA.7F8	VOA (Post ATI)	Isolate	This study	Dual								no	no	
A08.VOA.7C1	VOA (Post ATI)	Isolate	This study	X4								no	no	
A08.VOA.8E8	VOA (Post ATI)	Isolate	This study	Dual								no	no	
A08.REB.5C2	Rebound	Isolate	This study	R5						yes	yes	yes	no	yes
A08.REB.5D2	Rebound	Isolate	This study	X4						no	no	no	no	no
A08.REB.6B3	Rebound	Isolate	This study	R5						yes	yes	no	no	no
A08.REB.6D6	Rebound	Isolate	This study	X4	>20	>20				no	no	no	no	no
A08.REB.7C1	Rebound	Isolate	This study	X4						no	no	no	no	no
A08.REB.7C2	Rebound	Isolate	This study	R5						no	yes	yes	no	no
A08.REB.7D3	Rebound	Isolate	This study	X4	>20	>20				no	no	no	no	no
A08.REB.8D1	Rebound	Isolate	This study	X4	>20	>20						no	no	no
A08.REB.8A5	Rebound	Isolate	This study	X4	>20	>20						no	no	no
A08.REB.1A5	Rebound	IMC	This study	X4			no	no	no	no	no	no	no	no
A08.REB.2F4	Rebound	IMC	This study	R5			no	yes	yes	no	no	yes	yes	yes
A09.REB.1A5	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
A09.REB.1A2	Rebound	IMC	This study	R5			no	yes	yes	yes	yes	yes	yes	yes
S22.REB.1F5	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
S22.REB.3B6	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
S23.REB.3D1	Rebound	Isolate	This study	R5	>20	11.63	no	yes		yes	yes			
004.REB.4D1	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
004.REB.4E3	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
004.REB.4E6	Rebound	Isolate	This study	R5	>20	>20	no	yes		yes	yes			
601.REB.r1	Rebound	IMC	This study	R5			no	yes	yes	yes	yes	yes	yes	yes

\*Using CD14 selection, monocytes were isolates from peripheral blood mononuclear cells of 8 healthy donors, and cultured in M-CSF containing media to allow differentiation into macrophages. Virus replication was monitored for 20 days by measuring p24 antigen in culture supernatants. "yes" denotes p24 production above 0.5ng/ml.